CL2017001903A1 - Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante - Google Patents

Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante

Info

Publication number
CL2017001903A1
CL2017001903A1 CL2017001903A CL2017001903A CL2017001903A1 CL 2017001903 A1 CL2017001903 A1 CL 2017001903A1 CL 2017001903 A CL2017001903 A CL 2017001903A CL 2017001903 A CL2017001903 A CL 2017001903A CL 2017001903 A1 CL2017001903 A1 CL 2017001903A1
Authority
CL
Chile
Prior art keywords
transplantation
increasing
efficiency
stem cell
hematopoietic stem
Prior art date
Application number
CL2017001903A
Other languages
English (en)
Inventor
Michael Freissmuth
Eva-Maria Zebedin-Brandl
Zahra Kazemi
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Publication of CL2017001903A1 publication Critical patent/CL2017001903A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA EL USO NUEVO DE LA COMPOSICIÓN QUE COMPRENDE AL MENOS UN INHIBIDOR DE DIPEPTIDILPEPTIDASA IV (DPP-IV) PARA IMPLEMENTAR LA MIGRACIÓN Y EMIGRACIÓN DE LAS CÉLULAS PROGENITORAS HEMATOPOYÉTICAS EN RECEPTORES TRASPLANTADOS CON CÉLULAS MADRE, EN DONDE SE HAN TRATADO LAS CÉLULAS PROGENITORAS Y/O CÉLULAS MADRE HEMATOPOYÉTICAS IN VITRO CON UN COMPUESTO POTENCIADOR DE INJERTO, EN ESPECÍFICO CON UN ANÁLOGO DE PROSTACICLINA Y UN POTENCIADOR DE CAMP ANTES DE TRASPLANTE.</p>
CL2017001903A 2015-01-27 2017-07-25 Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante CL2017001903A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15152664 2015-01-27

Publications (1)

Publication Number Publication Date
CL2017001903A1 true CL2017001903A1 (es) 2018-03-23

Family

ID=52449965

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001903A CL2017001903A1 (es) 2015-01-27 2017-07-25 Composición novedosa para uso en el incremento de eficacia de injerto de células madre hematopoyéticas después del trasplante

Country Status (25)

Country Link
US (1) US10226465B2 (es)
EP (1) EP3250202B1 (es)
JP (1) JP6669762B2 (es)
KR (1) KR102577669B1 (es)
CN (1) CN107548305A (es)
AU (1) AU2016212090B2 (es)
BR (1) BR112017016077A2 (es)
CA (1) CA2973146C (es)
CL (1) CL2017001903A1 (es)
CY (1) CY1124317T1 (es)
DK (1) DK3250202T3 (es)
EA (1) EA039149B1 (es)
ES (1) ES2872698T3 (es)
HR (1) HRP20210930T1 (es)
HU (1) HUE054615T2 (es)
IL (1) IL253389B (es)
LT (1) LT3250202T (es)
PL (1) PL3250202T3 (es)
PT (1) PT3250202T (es)
RS (1) RS61945B1 (es)
SG (1) SG11201705812SA (es)
SI (1) SI3250202T1 (es)
SM (1) SMT202100465T1 (es)
UA (1) UA122488C2 (es)
WO (1) WO2016120310A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509863A (ja) 2013-03-15 2016-04-04 ラーソン、マルクス カーレ、トールレイフＬＡＲＳＳＯＮ， Ｍａｒｃｕｓ Ｋａｒｅ， Ｔｏｒｌｅｉｆ 細胞、臍帯血収集のための方法及び装置、並びに細胞の単離のための方法及び装置
WO2018073615A1 (en) * 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
US11213546B2 (en) 2017-09-07 2022-01-04 Emory University Methods to mobilize tissue resident cells for adoptive t cell therapy
WO2020047236A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
WO2020256628A1 (en) 2019-06-20 2020-12-24 Amniotics Ab An apparatus for filtering amniotic fluid
JP7714535B2 (ja) 2019-10-18 2025-07-29 アムニオティクス・アーベー 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置
EP4196260A4 (en) * 2020-08-14 2025-04-30 Navan Technologies, Inc. METHODS AND APPARATUS FOR DELIVERING BIOMOLECULES TO PRIMARY HUMAN HEMATOPOIETIC STEM CELLS USING NANOSTRAWS
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
CN112961827B (zh) * 2021-04-25 2024-04-26 河南省肿瘤医院 佛司可林在t细胞培养中的应用
WO2025172541A1 (en) 2024-02-15 2025-08-21 Aop Orphan Pharmaceuticals Gmbh New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
RU2008116578A (ru) 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
EP2117543A4 (en) * 2007-02-01 2011-09-28 Nephrogen Llc POTENTIALIZATION OF THE IMPLANTATION OF STEM CELLS AND TREATMENT OF ORGAN DYSFUNCTION OR BODY INSUFFICIENCY
WO2009152186A1 (en) * 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
WO2012074676A2 (en) 2010-11-09 2012-06-07 Emory University Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto
ES2693622T3 (es) 2011-01-13 2018-12-13 SciPharm S.à r.l. Método para mejorar el injerto de células madre hematopoyéticas
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US20140288010A1 (en) * 2013-02-22 2014-09-25 Georgia Regents Research Institute, Inc. Compositions and Methods for Increasing Stem Cell Survival

Also Published As

Publication number Publication date
SI3250202T1 (sl) 2021-07-30
CY1124317T1 (el) 2022-07-22
EP3250202A1 (en) 2017-12-06
HRP20210930T1 (hr) 2021-09-03
AU2016212090A1 (en) 2017-08-03
SG11201705812SA (en) 2017-08-30
DK3250202T3 (da) 2021-05-31
CA2973146C (en) 2024-01-09
JP2018505171A (ja) 2018-02-22
BR112017016077A2 (pt) 2018-04-03
IL253389A0 (en) 2017-09-28
SMT202100465T1 (it) 2021-09-14
AU2016212090B2 (en) 2021-05-20
HUE054615T2 (hu) 2021-09-28
UA122488C2 (uk) 2020-11-25
LT3250202T (lt) 2021-06-25
KR20170106980A (ko) 2017-09-22
PT3250202T (pt) 2021-06-17
KR102577669B1 (ko) 2023-09-12
JP6669762B2 (ja) 2020-03-18
CA2973146A1 (en) 2016-08-04
CN107548305A (zh) 2018-01-05
EP3250202B1 (en) 2021-03-10
IL253389B (en) 2021-02-28
EA039149B1 (ru) 2021-12-10
RS61945B1 (sr) 2021-07-30
PL3250202T3 (pl) 2021-08-30
EA201791703A1 (ru) 2017-11-30
US20180008606A1 (en) 2018-01-11
ES2872698T3 (es) 2021-11-02
US10226465B2 (en) 2019-03-12
WO2016120310A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
MX2018004475A (es) Agentes biologicos y su uso en plantas.
SG11202104084WA (en) Methods for allogeneic hematopoietic stem cell transplantation
UY36475A (es) Composiciones y metodos para el uso de insecticida con bacillus sp d747
NI201100083A (es) Compuestos que expanden células madre hematopoyéticas.
MX2016016076A (es) Composiciones de celulas t mejoradas.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
MX2016015004A (es) Uso de moleculas pequeñas para mejorar la expresion de mafa en celulas endocrinas pancreaticas.
AR085507A1 (es) Animales modificados geneticamente y metodos para su obtencion
EP4647498A3 (en) Improved reprogramming methods and cell culture platforms
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
DOP2013000240A (es) Composiciones y métodos para transferencia de energía mitocondrial de línea germinal autóloga
CY1124317T1 (el) Συνθεση για χρηση στην αυξηση αποτελεσματικοτητας εμφυτευσης αιματοποιητικων αρχεγονων κυτταρων μετα απο μεταμοσχευση
DK3749334T3 (da) Allogen hæmatopoietisk stamcelletransplantation
BR112017015130A2 (pt) cultivação de célula a longo prazo usando membrana de poliimida porosa e método de criopreservação de células usando membrana de poliimida porosa
AR099500A1 (es) Composición para el desmucilaginado enzimático de aceite
IL260858B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
WO2015171852A3 (en) Methods and compositions for non-cytotoxic stem cell transplantation
IL285274A (en) Calcineurin inhibitor resistant immune cells for use in adoptive cell transfer therapy
MX2016012102A (es) Metodos relacionados con celulas pluripotentes.
AR102376A1 (es) Método de tratamiento para anti-brote de tubérculos con cantidad reducida de cipc
CO6831974A2 (es) Usos, métodos y composiciones biológicas del genero paecilomyces para el control, prevención y erradicación de fitoparásitos en cultivos de solanáceas
BR112019000216A2 (pt) uso de removedores de gama-cetoaldeídos reativos para prolongar a vida útil de célula e tempo de saúde
AR102044A1 (es) Elementos reguladores de plantas y métodos para usarlos
CL2017002560A1 (es) Promotor de plantas para la expresión transgénica
EP4009991A4 (en) ANTI-VIRAL CENTRAL MEMORY CD8+ VETO CELLS IN HAPLOIDENTIC STEM CELL TRANSPLANTATION